Copeptin as a novel marker predicting prognosis of liver cirrhosis and its major complications
Received 15 May 2018
Accepted for publication 26 June 2018
Published 4 September 2018 Volume 2018:10 Pages 87—93
Checked for plagiarism Yes
Review by Single-blind
Peer reviewers approved by Dr Colin Mak
Peer reviewer comments 2
Editor who approved publication: Dr Gerry Lake-Bakaar
Ahmed Khaled Tawfik,1 Amal Helmy,2 Mohamed Yousef,1 Sabry Abou-Saif,1 Abdelrahman Kobtan,1 Eman Asaad,1 Sherief Abd-Elsalam1
1Department of Tropical Medicine and Infectious Diseases, Faculty of Medicine, Tanta University, Tanta, Egypt; 2Department of Clinical Pathology, Faculty of Medicine, Tanta University, Tanta, Egypt
Objectives: The aim of the work was to assess the level of copeptin as a surrogate marker predicting the severity of liver diseases and its major complications.
Patients and methods: This was a cross-sectional study that included 40 patients and 10 controls and was performed in Tanta University Hospital between June 2016 and November 2016. The studied cases were divided into five groups: group I (10 patients): compensated cirrhosis; group II (10 patients): cirrhosis with gastrointestinal hemorrhage due to portal hypertension; group III (10 patients): cirrhosis with hepatorenal syndrome; group IV (10 patients): cirrhosis with liver cell failure; and group V (10 controls): normal healthy individuals.
Results: Regarding serum copeptin in the studied groups, copeptin showed a significant decrease in group I vs group II‚ group I vs group III, and group I vs group IV; and there was a significant increase in group II vs group III‚ group II vs group IV‚ group II vs control‚ group III vs control, and group IV vs control. No significance was detected between group I vs control and group III vs group IV.
Conclusions: Copeptin is a novel marker for the determination of prognosis of liver cirrhosis. There is significant association between serum level of copeptin and complications of liver cirrhosis.
Keywords: cirrhosis, hepatorenal syndrome, liver failure, varices, prognosis
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]